Advaxis to Host Investor & Analyst Day on June 12
Focus on Patients, Partnerships and Progress
Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company developing cancer immunotherapies, today announced that it will host its annual Investor & Analyst Day on Monday, June 12, at 1:00 p.m. in New York, NY. The event will feature presentations followed immediately by a reception.
Event: Advaxis Investor & Analyst Day
Date:
Monday, June 12, 2017
Time:
1:00 – 4:00 p.m. ET, Reception from 4:00 – 5:00 p.m.
Location:
Offices of Reed Smith
599 Lexington Avenue, 22nd Floor
New York, NY 10022
At this year’s Investor & Analyst Day, Advaxis will focus on “Patients, Partnerships and Progress” with presentations centering around the following areas:
Clinical Trial Update with Case Study Highlights
Plans for Data Dissemination and Timelines
Update on Advaxis’ Corporate Collaborations
Research Update on the NEO and HOT Programs
Progress Towards Regulatory Submission and Commercial Readiness
During the Investor & Analyst Day, several investigators involved in Advaxis’ ongoing clinical trials will highlight their experiences and case studies in an interactive clinical symposium. An update will be provided on the company’s global Phase 3 AIM2CERV study, as well as a planned potentially registrational quality study of axalimogene filolisbac for the treatment of metastatic cervical cancer. In addition, the team will review the plans to file for marketing authorization for axalimogene filolisbac in the European Union this year, an update on the clinical collaboration with Amgen, Inc. on ADXS-NEO and more.
At this year’s Investor & Analyst Day, Advaxis will focus on “Patients, Partnerships and Progress” with presentations centering around the following areas:
Clinical Trial Update with Case Study Highlights
Plans for Data Dissemination and Timelines
Update on Advaxis’ Corporate Collaborations
Research Update on the NEO and HOT Programs
Progress Towards Regulatory Submission and Commercial Readiness
During the Investor & Analyst Day, several investigators involved in Advaxis’ ongoing clinical trials will highlight their experiences and case studies in an interactive clinical symposium. An update will be provided on the company’s global Phase 3 AIM2CERV study, as well as a planned potentially registrational quality study of axalimogene filolisbac for the treatment of metastatic cervical cancer. In addition, the team will review the plans to file for marketing authorization for axalimogene filolisbac in the European Union this year, an update on the clinical collaboration with Amgen, Inc. on ADXS-NEO and more.
